Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX 75390-9047, USA.
Arterioscler Thromb Vasc Biol. 2011 Sep;31(9):2136-43. doi: 10.1161/ATVBAHA.111.228692. Epub 2011 Aug 4.
Pulmonary surfactant protein B (SP-B), an alveolar protein normally detectable at only very low concentrations in blood, circulates at higher levels among smokers and those with alveolar injury and inflammation. We hypothesized that SP-B may serve as a marker of the vascular effects of smoking and would thus be associated with subclinical measures of atherosclerosis.
Plasma levels of SP-B were measured in 3294 subjects, ages 30 to 65, enrolled in the Dallas Heart Study, a probability-based population sample of Dallas County adults. Coronary artery calcium (CAC) was measured by computed tomography and abdominal aortic plaque (AP) by magnetic resonance imaging. The cohort comprised 29% current and 17% former smokers. The overall prevalence of CAC was 22%, and that of AP was 39%. Median SP-B levels were 5-fold higher among current versus never smokers (P<0.0001) and were significantly correlated with estimated pack-years smoked (Spearman ρ=0.35, P<0.0001). Increasing levels of SP-B also associated with other traditional cardiac risk factors and higher levels of inflammatory biomarkers. In univariable analyses, increasing SP-B quartiles associated with higher prevalence of both CAC and AP (P(trend)<0.0001 for each). In multivariable analyses adjusting for traditional cardiovascular risk factors, SP-B remained associated with AP (OR 1.87 for the 4th versus 1st quartiles, 95% confidence interval 1.39 to 2.51; P<0.0001) but not CAC. An interaction was observed between SP-B, smoking status, and AP (P(interaction)=0.01), such that SP-B associated with AP in current smokers (adjusted OR 2.15 for the 4th versus 1st quartile, 95% confidence interval 1.26 to 3.67; P=0.005) but not in former or never smokers.
Circulating levels of SP-B increase with greater smoking burden and independently associate with abdominal AP among current smokers. Our findings support further investigation of the role of SP-B as a marker of the vascular effects of smoking.
肺表面活性蛋白 B(SP-B)是一种肺泡蛋白,正常情况下在血液中只能检测到极低的浓度,但在吸烟者和肺泡损伤及炎症患者中循环水平较高。我们假设 SP-B 可能作为吸烟对血管影响的标志物,因此与亚临床动脉粥样硬化程度相关。
在达拉斯心脏研究中,对 3294 名 30 至 65 岁的受试者进行了血浆 SP-B 水平的检测,这是达拉斯县成年人的一项基于概率的人群样本。通过计算机断层扫描测量冠状动脉钙(CAC),通过磁共振成像测量腹主动脉斑块(AP)。该队列包括 29%的现吸烟者和 17%的前吸烟者。CAC 的总体患病率为 22%,AP 为 39%。现吸烟者的 SP-B 中位数水平比从不吸烟者高 5 倍(P<0.0001),且与估计的吸烟包年数呈显著相关(Spearman ρ=0.35,P<0.0001)。SP-B 水平的升高也与其他传统心脏危险因素和更高水平的炎症生物标志物相关。在单变量分析中,SP-B 四分位递增与 CAC 和 AP 的患病率增加相关(每种情况 P(trend)<0.0001)。在调整传统心血管危险因素的多变量分析中,SP-B 与 AP 仍然相关(第 4 四分位与第 1 四分位相比,比值比为 1.87,95%置信区间为 1.39 至 2.51;P<0.0001),但与 CAC 无关。在 SP-B、吸烟状态和 AP 之间观察到交互作用(P(interaction)=0.01),即 SP-B 与当前吸烟者的 AP 相关(第 4 四分位与第 1 四分位相比,调整后的比值比为 2.15,95%置信区间为 1.26 至 3.67;P=0.005),而与前吸烟者或从不吸烟者无关。
循环 SP-B 水平随吸烟量的增加而增加,并与当前吸烟者的腹主动脉 AP 独立相关。我们的研究结果支持进一步研究 SP-B 作为吸烟对血管影响的标志物的作用。